Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1) - Takeaways - MDSpire

Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1)

  • By

  • Yoshio Nakamura

  • Naoya Yamazaki

  • Kenjiro Namikawa

  • Hiroshi Uchi

  • Shoichiro Mori

  • Mariko Ogawa-Momohara

  • Taku Fujimura

  • Tatsuya Takenouchi

  • Mana Kurimoto

  • Yuki Yamamoto

  • Atsushi Otsuka

  • Kenji Kabashima

  • Takayuki Fusumae

  • Ikuko Hirai

  • Keiji Tanese

  • Yasuko Saito

  • Masayuki Amagai

  • Ryo Takemura

  • Yasunori Sato

  • Takeru Funakoshi

  • March 4, 2026

  • 0 min

Share

  • 1

    Nivolumab was evaluated in a Phase II trial for advanced unresectable cutaneous epithelial malignancies in Japanese patients.

  • 2

    The study included patients with advanced cSCC and non-cSCC NMSCs, focusing on safety and antitumor activity.

  • 3

    Patients received nivolumab every 4 weeks for up to 26 cycles, with possible extension for those showing response.

  • 4

    The trial aimed to enroll 30 patients to achieve sufficient statistical power for evaluating treatment efficacy.

  • 5

    Nivolumab's potential benefits were anticipated due to the high tumor mutational burden in several non-cSCC NMSCs.

Original Source(s)

Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1)

  • by Yoshio Nakamura, Naoya Yamazaki, Kenjiro Namikawa, Hiroshi Uchi, Shoichiro Mori, Mariko Ogawa-Momohara, Taku Fujimura, Tatsuya Takenouchi, Mana Kurimoto, Yuki Yamamoto, Atsushi Otsuka, Kenji Kabashima, Takayuki Fusumae, Ikuko Hirai, Keiji Tanese, Yasuko Saito, Masayuki Amagai, Ryo Takemura, Yasunori Sato, Takeru Funakoshi

  • March 4, 2026

Related Content

Discrepancies Identified in the Figures

  • April 1, 2026

High-frequency ultrasound combined with superb microvascular imaging for differential diagnosis of basal cell carcinoma and seborrheic keratosis: a retrospective analysis with nomogram implementation

From Sophie Spitz to Molecular Melanocytoma

How one woman's pioneering research transformed pediatric melanoma diagnosis